Navigation Links
AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
Date:10/5/2007

Presentation to Include the Recently Released Strong Results from the Latest Pre-FDA Multi-Hospital Study using the AppyScore Human Appendicitis

Blood-based Screen / Triage Test

CASTLE ROCK, Colo., Oct. 5 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the Oppenheimer Best Ideas 1x1 Conference, scheduled for October 11, 2007, at the Hilton Boston Financial District in Boston, Massachusetts.

This annual Oppenheimer & Co. event will introduce AspenBio to select institutional investors and buyside analysts in a series of one-on-one presentations and meetings designed to provide a highly effective environment for evaluating several small cap companies with extraordinary potential.

Oppenheimer & Co. recently initiated coverage of AspenBio Pharma. The medical analyst who authored the report said he did not know of any other company developing a blood test that can rule out appendicitis, and a test for appendicitis has the potential to revolutionize emergency medicine, decrease unnecessary surgeries, reduce cost significantly, and save many lives.

AspenBio will discuss with conference attendees the strong results as recently announced from its latest pre-FDA multiple-hospital study using its AppyScore human appendicitis screen and triage blood test. Announced on September 28, the results indicated the sensitivity of the screen test was 98% in the large study. The study also demonstrated that a significant percentage of CT scans could potentially be avoided leading to important patient health, medical utility and cost benefits. The study showed 58% of unnecessary surgeries could have been avoided, which also further exemplifies how this new appendicitis screen testing concept can provide exciting new capabilities and benefits for emergency medicine. The high level of sensitivity also means the test could reduce the risk of sending patients home because of a false negative diagnosis.

About Oppenheimer & Co. Inc.

Oppenheimer & Co. is a leading national investment boutique that provides financial services and advice to high net worth investors, individuals, businesses and institutions. For over 120 years, we have provided investors with the necessary expertise and insight to meet the challenge of achieving their financial goals. Our commitment to our clients' investment needs, our experienced and dedicated professionals, and our proud tradition empower us to deliver effective and innovative solutions to our clients.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit: http://www.aspenbiopharma.com.

For more information contact

AspenBio Pharma, Inc.

Gregory Pusey, Chairman

Tel 303-722-4008

Investor Relations

Liolios Group, Inc.

Scott Liolios or Ron Both

Tel 949-574-3860


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):